Opioid Seller Seeks To Lead Antitrust Class Despite Charges

Law360, Boston (July 26, 2019, 7:39 PM EDT) -- Pharmaceutical distributor Rochester Drug Co-Operative, which admitted to unlawful opioid sales earlier this year, argued in Boston federal court Friday that it is reformed and can dutifully serve as a class representative in an antitrust pay-for-delay suit over the sales of ADHD medication Intuniv.

Peter Kohn of Faruqi & Faruqi LLP, representing RDC, told U.S. District Judge Allison D. Burroughs the company is under new management and said its motives for leading the proposed class action — which alleges an illegal reverse payment from Shire LLC to Actavis LLC to delay generic competition for Intuniv — are pure. Kohn quoted from a deposition of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!